A review of vascular disrupting agents as a concomitant anti-tumour modality with radiation

E-ISSN： 1467-1131|12|3|255-262

ISSN： 1460-3969

Source： Journal of Radiotherapy in Practice, Vol.12, Iss.3, 2013-05, pp. : 255-262

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Update on vascular disrupting agents for cancer therapy

By Korpanty Grzegorz Brekken Rolf A

Therapy, Vol. 8, Iss. 4, 2011-07 ,pp. : 403-413

Future Medicine

Access to resources Recommend Favorite

Entinostat, a novel histone deacetylase inhibitor is active in B‐cell lymphoma and enhances the anti‐tumour activity of rituximab and chemotherapy agents

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 4, 2015-05 ,pp. : 506-519

John Wiley & Sons Inc

Access to resources Recommend Favorite

Applying gold nanoparticles as tumor-vascular disrupting agents during brachytherapy: estimation of endothelial dose enhancement

By Ngwa Wilfred Makrigiorgos G Mike Berbeco Ross I

Physics in Medicine and Biology, Vol. 55, Iss. 21, 2010-11 ,pp. : 6533-6548

IOP Publishing

Access to resources Recommend Favorite

Hypertension and vascular dementia in the elderly: the potential role of anti-hypertensive agents

By Coca Antonio

Current Medical Research and Opinion, Vol. 29, Iss. 9, 2013-09 ,pp. : 1045-1054

Informa Healthcare

Access to resources Recommend Favorite

Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model

By Ambruosi Alessandra Gelperina Svetlana Khalansky Alexander Tanski Sandra Theisen Alf Kreuter Jörg

Journal of Microencapsulation, Vol. 23, Iss. 5, 2006-08 ,pp. : 582-592

Informa Healthcare

Access to resources Recommend Favorite